Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo

Leukemia Research

Volumn 28, Issue 2, 2004, Pages 139-147

  Friedberg, Jonathan W ^a   Dong, Danielle A ^b   Li, Sigui ^b   Kim, Helen ^b   Stephans, Katherine ^b   Noonan, Kimberly ^b   Neuberg, Donna ^b   Gribben, John G ^b,c,e   Fisher, David C ^b,c,e   Freedman, Arnold S ^b,c,e   Takvorian, Tak ^d,e   Jurgens, Ray ^f   Battle, Traci E ^b   Frank, David A ^b,c,e  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BAYER AG   (Germany)

Author keywords

CD38; CLL; Flow cytometry; Oral fludarabine; Purine analog therapy; STAT1

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMINOTRANSFERASE; COTRIMOXAZOLE; FLUDARABINE; PURINE DERIVATIVE; STAT1 PROTEIN; TUMOR MARKER; ZK 153851;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHROPATHY; BLOOD SAMPLING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE MARKER; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLOW CYTOMETRY; GOUT; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTOSIS; LIVER TOXICITY; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; RASH; RETINA DETACHMENT; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

EID: 10744230714     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00213-3     Document Type: Conference Paper

References (34)

1. Call T.G., Noel P., Habermann T.M., Beard C.M., O'Fallon W.M., Kurland L.T. Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989. Mayo. Clin. Proc. 69(4):1994;315-322.
2. Zent C.S., Kyasa M.J., Evans R., Schichman S.A. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer. 92(5):2001;1325-1330.
3. Kipps T.J. Chronic lymphocytic leukemia. Curr. Opin. Hematol. 7(4):2000;223-234.
4. Chun H.G., Leyland-Jones B., Cheson B.D. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J. Clin. Oncol. 9(1):1991;175-188.
5. Leporrier M., Chevret S., Cazin B., Boudjerra N., Feugier P., Desablens B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 98(8):2001;2319-2325.
6. Rai K.R., Peterson B.L., Appelbaum F.R., Kolitz J., Elias L., Shepherd L., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343(24):2000;1750-1757.
7. Foran J.M., Oscier D., Orchard J., Johnson S.A., Tighe M., Cullen M.H., et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J. Clin. Oncol. 17(5):1999;1574-1579.
8. Boogaerts M.A., Van Hoof A., Catovsky D., Kovacs M., Montillo M., Zinzani P.L., et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 19(22):2001;4252-4258.
9. Sorensen J.M., Vena D.A., Fallavollita A., Chun H.G., Cheson B.D., et al. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J. Clin. Oncol. 15(2):1997;458-465.
10. Frank D.A. STAT signaling in the pathogenesis and treatment of cancer. Mol. Med. 5(7):1999;432-456.
11. Frank D.A., Mahajan S., Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J. Clin. Invest. 100(12):1997;3140-3148.
12. Frank D.A., Mahajan S., Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat. Med. 5(4):1999;444-447.
13. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. J. Clin. Oncol. 17(12):1999;3835-3849.
14. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., O'Brien S., et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 87(12):1996;4990-4997.
15. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343(26):2000;1910-1916.
16. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
17. Battle T.E., Frank D.A. The role of STATs in apoptosis. Curr. Mol. Med. 2(4):2002;381-392.
18. Gonzalez H., Leblond V., Azar N., Sutton L., Gabarre J., Binet J.L., et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol. Cell Ther. 40(3):1998;113-118.
19. Rossi J.-F., Hoof A.V., Bock R.D., Johnson S.A., Bron D., Foussard D., et al. Oral fludarabine phosphate as first-line treatment of chronic lymphocytic leukemia. Blood. 100(11):2002;384a.
20. DeMario M.D., Ratain M.J. Oral chemotherapy: rationale and future directions. J. Clin. Oncol. 16(7):1998;2557-2567.
21. Greco F.A. Evolving role of oral chemotherapy for the treatment of patients with neoplasms. Oncology (Huntingt). 12(3 (Suppl. 4)):1998;43-50.
22. Lee C.R., Nicholson P.W., Souhami R.L., Deshmukh A.A. Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J. Clin. Oncol. 10(6):1992;1007-1013.
23. Remick S.C., Sedransk N., Haase R.F., Blanchard C.G., Ramnes C.R., Nazeer T., et al. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. Am. J. Hematol. 66(3):2001;178-188.
24. Navarro R.P., Morrow T., Baran R. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Manage. Care Interface. 15(7):2002;55-62.
25. Cazin B., Maloum K., Divine M., Lepretre S., Travade P., Delmer A., et al. Oral fludarabine and cyclophosphamide in previously untreated CLL: preliminary data on 75 patients. Blood. 100(11):2002;206a.
26. Wierda W.G., Cantwell M.J., Woods S.J., Rassenti L.Z., Prussak C.E., Kipps T.J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 96(9):2000;2917-2924.
27. Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps TJ, et al. In vivo activation of STAT1 following CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin. Cancer Res. 2003 [in press].
28. Battle T., Frank D. Activation of the STAT signalling pathway is required for CLL differentiation in response to bryostatin 1. Blood. 98:2001;472a.
29. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 94(6):1999;1840-1847.
30. Ibrahim S., Keating M., Do K.A., O'Brien S., Huh Y.O., Jilani I., et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 98(1):2001;181-186.
31. Del Poeta G., Maurillo L., Venditti A., Buccisano F., Epiceno A.M., Capelli G., et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 98(9):2001;2633-2639.
32. Hamblin T.J., Orchard J.A., Ibbotson R.E., Davis Z., Thomas P.W., Stevenson F.K., et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 99(3):2002;1023-1029.
33. Ghia P., Guida G., Stella S., Gottardi D., Geuna M., Strola G., et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood. 101(4):2003;1262-1269.
34. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348:2003;1764-1775.